21 / 28
IIIa
PFS m
OS m
RTOG 9410
1
43%
17
Metanálisis
2
37%
~11
~14 (23.8% 3a)
PROCLAIM
3
46.5% - 47.8%
11.4 vs 9.8
26.8 vs 25
RTOG 0617
4
66%- 63% - 65% - 66% 11.8 vs 9.8 vs 10.8 vs 10.7
28 vs 20.3 vs 25 vs 24
Docetaxel consolidation
5
42.5% - 39.2%
~9
23.2 vs 21.2
Tecemotide
6
39%
10 - 8.4 (TTP)
30.8 vs 20.6*
Tecemotide-Japanese
7
35.1%-34.5%
12.1 - 9.1*
32.4 vs 36.5*
PACIFIC
52.9% - 52.7%
16.8 vs 5.6
1
Curran WJ. J Nat Cancer Inst 2011;103:1452-1460
2
Aupérin A. J Clin Oncol 2010;28:2181-90
3
Senan S. J Clin Oncol 2016;34:953-962
4
Bradley JD. Lancet Oncol 2015;16:187-199
5
Hanna N. J Clin Oncol 2008;26:5755-5760
6
Butts C.Lancet Oncol 2014; 15: 59–68
7
Katakami N. Lung Cancer 2017;105:23-30